Here is Lilly's home page on the web. http://www.lilly.com/company/ Eli Lilly and Company P.O. Box 88665 Indianapolis, Indiana 46208-0665 Lilly's World Wide Web address on the Internet is http://www.lilly.com Abbott Laboratories One Abbott Park Road Abbott Park, Illinois 60064-3500 another good place to check is National Association of the Mentally Ill (NAMI). As a client advocacy association they stay on top of these things and report both pros and cons of all these meds. It is really quite an impressive organization. http://www.nami.org/ also I did find one article I have on some of the newer antipsychotics: Clozapine,olanzapine, quetiapine, sertindole, and ziprasidone. Quoting from this: Olanzapine--a thienobenzodiazepine compoind previously designated LY - 170053 -- has high affinity for D1, D2, D3, D4, 5HT3, 5HT6, alpha1-adrenergic, muscarinic M1, and histaminic H1 receptors: affinity for the alpha2 - adrenergic receptor is negligible. The affinity of the drug for 5HT2 receptors is about twice as high as for D2 receptors and is only slightly lower than the ration of these activities reported for clozapine. this ratio has been suggested as one basis for clozapine's exceptional clinical benefit in the treatment of psychosis raising the possibility that olanzapine may show similar efficacy. . . Olanzapine thus appears to be effective and well tolerated at dosages of 7.5-20 mg/day. It's apparent effectiveness against negative symptoms is especially encouraging. However, a recent, pre-clinical animal study reported on olanzapine's ability to increase the number of Fos- like immunoreactive (FLI) neurons in the dorsolateral striatum (which plays a signigicant role in the regulation of movement) suggesting that higher doses of this compound may produce EPS. this finding, if corroborated in research with human subjects, will figure prominently in the clinical use of olanzapine because higher dosages have proved more effective than low or intermediate dosages so far, therefore, "unlike clozapine and perhaps more like risperidone... there will exist a dose window [for olanzapine] at which antipsychotic activity can be produced in the absence of signigicant EPS." Jibson, M.D., and Tandon, R. (1996). A summary of research findings on the new antipsychotic drugs. The Psychiatry Forum, 16 (May). another good article which discusses these new meds can be accessed online at: http://www.nami.org/medicat/choosing.htm Schizophrenia Treatment: Questions To Ask Your Doctor For Choosing The Right Medication by S. Charles Schulz, M.D., and Peter F. Buckley, M.D. Note: Dr. Schulz is a professor and the chairman of the Department of Psychiatry at Case Western University and director of the Department of Psychiatry at the University Hospitals of Cleveland. Dr. Buckley is an associate professor at Case Western and the medical director for the Northcoast Behavioral Health Care System.
